Introduction
============

Uridine and cytidine are substances belonging to the pyrimidine nucleotide family, which in turn comprises one of four main classes of biological molecules (along with carbohydrates, lipids, and proteins) that play several fundamental roles in cellular metabolism. Aside from being components of DNA and participating in genome transcription and translation, functions of these nucleotides include energy transfer for chemical bonding, intracellular signaling, neurotransmission, and transfer of biochemical radicals from intermediate metabolism.[@b1-jpr-10-397]

Vitamin B~12~ is essential in the human body for growth and maintenance of a variety of processes, including cell reproduction and synthesis of myelin and nucleoproteins, and must be supplied from an exogenous source.[@b2-jpr-10-397] Adequate vitamin B~12~ levels in the body depend on adequate ingestion and absorption (requiring an acid-pepsin complex in the stomach that releases cobalamin from its binding proteins, pancreatic proteins that release cobalamin from the R factor bond, secretion of intrinsic factor by gastric parietal cells in order to bind cobalamin, and the presence of cobalamin and intrinsic factor receptors in the ileum.[@b3-jpr-10-397],[@b4-jpr-10-397] Vitamin B~12~ is important to nerve metabolism via the remethylation of homocysteine to methionine for de novo synthesis of s-Adenosyl methionine.[@b5-jpr-10-397] Vitamin B~12~ deficiency can be caused by numerous factors, usually some combination of inadequate ingestion and absorption.[@b6-jpr-10-397] Deficiency can lead to megaloblastic anemia and neurological alterations, the latter likely linked to the absence of s-Adenosyl methionine formation.[@b7-jpr-10-397], [@b8-jpr-10-397]

This trial assessed treatment outcomes following administration of a combination of uridine triphosphate trisodium (UTP), cytidine monophosphate disodium (CMP), and vitamin B~12~ in the treatment of patients with compressive neuralgias. There is a body of clinical and preclinical evidence in the literature, supporting use of CMP and UTP in neuropathic pain, with potential symptomatic benefits.[@b9-jpr-10-397]--[@b22-jpr-10-397]

Several preclinical studies of peripheral neuropathies of varying etiologies have indicated beneficial effects of UTP and CMP administration in situations such as experimentally induced crush injury. Reported preclinical observations include accelerated nerve and muscle fiber regeneration, increased nerve conduction velocity, increased levels of neuritic protein neurofilaments, increased axon myelin surface area and thickness, and increased levels of neuronal cell membrane phospholipids phosphatidylcholine and phosphatidylethanolamine following nucleotide administration.[@b19-jpr-10-397]--[@b22-jpr-10-397] In the clinical setting, the combination of UTP and CMP with vitamin B~12~ has been investigated in several painful conditions with favorable results, among which are diabetic neuropathy, acute non-traumatic pain, lumbar pain, cervical pain, and traumatic-compressive lesions.[@b10-jpr-10-397]--[@b13-jpr-10-397], [@b18-jpr-10-397]

Objectives
==========

The objectives of this study were to assess the safety and efficacy of the combination of nucleotides (UTP and CMP) and vitamin B~12~ in patients presenting with neuralgia arising from neural compression associated with degenerative orthopedic alterations and trauma, and to compare these effects with isolated administration of vitamin B~12~.

Materials and methods
=====================

This was a randomized, double-blind, comparative, controlled trial performed at UNIFESO Medical School facilities and hospital. The study was registered with the Brazilian National Database GGMED/GESF-ANVISA under the following numbers: NOTIFICAÇÃO EM PESQUISA CLÍNICA Nº 61/2014 Expediente do CE: 0331070141. After study approval by the UNIFESO ethical committee (approval no 509.682) and written informed consent of all participants, subjects meeting inclusion criteria were randomized to a 30-day oral treatment period. Inclusion criteria included patients of both genders, ≥18 years of age, with a clinical presentation of degenerative orthopedic alteration with neural compression. Female patients performed a urine pregnancy test prior to inclusion and were required to maintain adequate birth control throughout the study period. Exclusion criteria included need for surgical treatment and need for other analgesics.

Enrolled subjects were randomized by order of arrival to the study center into two treatment groups: Group A received the combination of nucleotides and vitamin B~12,~ while subjects in Group B received vitamin B~12~ monotherapy. The study drug and treatment regimen was two capsules, three times per day for Group A. Each capsule contained: CMP 2.5 mg; UTP 1.5 mg; and hydroxocobalamin 1.0 mg. Study treatment regimen for subjects in Group B was two capsules, three times per day, each capsule contained hydroxocobalamin 1.0 mg. There was no visible difference between the study drugs, in accordance with blinding procedures for double-blind trials. Subjects were instructed to swallow the capsules whole at breakfast, lunch, and dinner.

The study hypothesis was that the combination of nucleotides and vitamin B~12~ would show superior efficacy in relation to B~12~ monotherapy. The study protocol outlined three patient visits to the study center: pretreatment for screening, randomization, and study drug distribution; visit two took place after 15 days of treatment; and visit three occurred at the end of the 30-day treatment period. At each of these study visits, subjects underwent a series of efficacy and tolerability assessments.

Efficacy assessments included a 100 visual analog pain scale (VAS), and the Patient Functionality Questionnaire (PFQ), a 12-item yes or no questionnaire about management of daily needs. The assessment included sleep quality, need to rest, ability to get up, standing and climbing stairs, washing, drying, and dressing, picking up things from the floor, changing posture, carrying weight, and need for assistance from other people. At each assessment, the patient and the investigating physician also evaluated the patient's overall condition on a scale of 1--10 points. Safety assessments took into account vital signs at each assessment and occurrence, severity, and duration of any adverse effects, including changes in laboratory tests.

The primary study endpoint was the percentage of subjects presenting VAS ≤20 mm at end of study treatment period. Secondary study endpoints included the percentage of subjects presenting improvement ≥5 points on the PFQ; percentage of subjects presenting pain reduction (reduction in VAS scores at study end in relation to pretreatment); and number of subjects presenting adverse events.

Study sample size took into account the results of a previous study,[@b10-jpr-10-397] evaluating 80 subjects (40 per treatment group), in which mean VAS scores at end of treatment were 21.11 in the combination group versus 41.75 in the B~12~ monotherapy group. Thus, a study sample size of 400 was determined, taking into account the mean between group difference of 20.6mm and standard deviation of 10.3mm, from the previous study, with a standard error of 1.03. The 95% confidence interval was 18.58--22.62, with a power of 1.0 and a two-tailed alpha of 0.05. Data were statistically analyzed using the software GraphPad Prism 5.0. Overall clinical efficacy and tolerability were analyzed via comparison of the results of each assessment in relation to pretreatment values, within and between treatment groups. For categorical variables, we used the χ^2^ or Fisher's test, while continuous variables were analyzed using the repeated measures ANOVA or Student's *t*-test.

Results
=======

A total of 400 subjects were randomized to treatment, with 200 subjects per treatment group. [Figure 1](#f1-jpr-10-397){ref-type="fig"} shows the flow of subjects through the trial. No significant between-group differences were noted at pretreatment in the demographic data and pretreatment characteristics of the study population, as summarized in [Table 1](#t1-jpr-10-397){ref-type="table"}.

The safety measures monitored during the study are summarized in [Table 2](#t2-jpr-10-397){ref-type="table"}. Pretreatment safety measures did not vary significantly between Groups A and B: weight (*p*=0.148), body mass index (BMI) (*p*=0.532), blood pressure (*p*=1.0 for systolic blood pressure and *p*=0.849 for diastolic blood pressure), and heart rate (*p*=0.413). Throughout the treatment period within the treatment groups, with the exception of systolic blood pressure in both groups and diastolic blood pressure in Group B, there was no statistically significant change in weight (Group A, *p*=0.855; Group B, *p* =0.0603), BMI (Group A, *p* =0.6; Group B, *p* =0.257), blood pressure (Group A, *p* = 0.0013 for systolic blood pressure and *p*=0.133 for diastolic blood pressure; Group B, *p* =0.0046 for systolic blood pressure and *p*=0.0032 for diastolic blood pressure), and pulse (Group A, *p*=0.541; Group B, *p*=0.337).

Pretreatment PFQ scores were significantly lower among patients in Group B (median for Group A, 9.0; median for Group B, 8.0; *p*=0.0036). Median PFQ scores were 5.0 at visit two in both treatment groups and 0.0 at visit three in both treatment groups. Both groups showed statistically significant improvement at the end of the study in relation to pretreatment PFQ scores (*p*\<0.0001 for both treatment groups). In relation to the secondary study endpoint, there was no between-group difference in the percentage of subjects presenting improvement ≥5 points on the PFQ (*p*=0.135).

Pretreatment patient overall assessment scores were homogenous between treatment groups (*p*=0.29). At visits two and three, the scores of this assessment improved within each treatment group, but Group A patients showed a greater improvement in scores at both visit two (*p*=0.014) and visit three (*p*=0.0024) in comparison to Group B scores ([Figure 2](#f2-jpr-10-397){ref-type="fig"}). Physician overall assessment scores were also homogenous between treatment groups at pretreatment (*p*=0.717), but at visits two and three scores were significantly lower in Group A as compared to Group B (*p*=0.0029 for visit two and *p*=0.006 for visit three) ([Figure 3](#f3-jpr-10-397){ref-type="fig"}).

At pretreatment, mean VAS scores among the patients in Group A was 51.26mm (±12.38) while in Group B mean pretreatment VAS score was 51.06 (±11.72) (*p*=0.87). Visit two VAS scores for Group A and Group B were 29.86 mm (±12.94) and 33.88 mm (±11.86) (*p*=0.0014); At visit three, mean Group A VAS scores were 16.06 mm (±12.03) and 20.40 mm (±11.42) for Group B (*p*=0.0003). The percentage of subjects presenting VAS scores ≤20 mm (primary study endpoint) at visit three was significantly higher in Group A as compared to Group B (*p*=0.0425). Within the treatment groups, VAS score reduction was statistically significant for both Group A and Group B (*p*\<0.0001 for both groups) ([Figure 4](#f4-jpr-10-397){ref-type="fig"}).

Adverse events were recorded in both treatment groups, though for the most part these were not serious and were transient. [Table 3](#t3-jpr-10-397){ref-type="table"} summarizes the adverse events determined by the investigating physician to be related to the study drug. There was no between-group difference in the percentage of subjects presenting adverse events during the treatment period (*p*=0.6009).

Discussion
==========

We report the results of a clinical trial using the combination of uridine, cytidine, and vitamin B~12~ in the treatment of neuralgias caused by degenerative orthopedic alterations with neural compression. This combination is commercially available in Brazil under the brand name Etna^®^. The combination of the nucleotides with vitamin B~12~ yielded a more significant pain reduction as measured by the VAS. Assessments performed by both the patients and the investigating physician had higher scores after 15 and 30 days of treatment among subjects treated with the combination. Treatment with the combination and with the control of vitamin B~12~ monotherapy resulted in significant improvement in patient functionality throughout the treatment period, as measured by the patient functionality questionnaire.

The findings of this study are in agreement with those previously described in the literature. A previous study performed by Goldberg et al (2009) assessed the use of this combination in the treatment of back pain and hip pain, reporting significant reduction in pain assessments as well as functionality.[@b10-jpr-10-397] As with the study of Goldberg and also another recent study in alcoholic polyneuropathy in which the authors compared the use of the combination of UTP + CMP + vitamin B~12~ with the use of vitamin B~12~ monotherapy,[@b17-jpr-10-397] there was a significant improvement over the treatment period in pain manifestations as compared to the monotherapy group, although the patients within the monotherapy group also displayed significant improvement throughout the treatment as compared to pretreatment status. This finding and that of our study highlights the importance the vitamin B~12~ component in the treatment of these painful conditions.

A limitation of this study was the inclusion of three distinct pain locations: lower back, hip, and carpal tunnel syndrome which ultimately reduced the number of subjects in each pain subcategory. Future studies should focus on a single pain location in order achieve more specific results. Nevertheless, we believe the results of this study are in concordance with findings in the literature and serve to contribute to the growing body of evidence indicating the therapeutic value of the combination of UTP,CMP and vitamin B12 for the treatment of peripheral neuropathies. It is also important to point out that unlike vitamin B~12~ (which has been confirmed to exhibit antinociceptive effects in both animal and human studies) the nucleotides do not have any direct role in anti-inflammation or analgesia and thus the symptomatic improvements observed in our study and in previous studies are suggestive of structural neuroregeneration by the nucleotides as a mechanism of action.[@b10-jpr-10-397], [@b11-jpr-10-397], [@b14-jpr-10-397], [@b15-jpr-10-397] Indeed, previous studies on animal models give credence to this notion, with previous observations of the nucleotides playing a positive role in axon and myelin sheaths of nerve and muscle fibers during regeneration following experimentally-induced damage, in addition to improved nerve fiber conduction velocity.[@b19-jpr-10-397]--[@b21-jpr-10-397]

A combination of uridine, folic acid, and vitamin B~12~ was recently reported to be effective in the treatment of carpal tunnel syndrome. Although in a small scale exploratory trial of 48 subjects, authors reported reduced pain scores and improvement in symptom intensity following 60 days of treatment with the combination therapy.[@b23-jpr-10-397] An important limiting factor in our study with regards to carpal tunnel syndrome is the relatively small sample size in relation to the total patient population, as mentioned in the preceding paragraph. However, these findings together with the results of our study warrant further investigation into the use of the nucleotides and vitamin B~12~ in the treatment of this very common ailment.

Clinical trials of painful conditions attributable to neuropathic pain (pain following neurological surgical procedures, neural compression-induced neuralgias, chronic neuropathic lumbar pain, peripheral neuropathies, and pain and paresthesia related to B~12~ deficiency anemia) have consistently yielded encouraging results with use of the combination of uridine, cytidine, and vitamin B~12~, and further studies may reveal additional indications where this combination or others like it may be of use, while also expanding our understanding of the interaction between the nucleotides and vitamin B~12~ in painful conditions.[@b9-jpr-10-397]--[@b21-jpr-10-397] For instance, the combination of uridine, folic acid, and vitamin B~12~ was also reported to be effective in neuropathic pain of peripheral neuropathies, with a reduction in pain intensity and also allowing for reduction in concomitant medication use.[@b23-jpr-10-397],[@b24-jpr-10-397] These types of study are important to explore new alternatives for addressing neuropathic pain -- with the aim of providing treatment options that reduce pain, decreased need for other drugs with more unwanted side effects, and improve patient care and quality of life.

Conclusion
==========

The results of this study showed a more expressive improvement in efficacy evaluations among subjects treated with the combination of nucleotides + vitamin B~12~, with a statistically significant superiority of the combination in pain reduction (evidenced by VAS scores). There were adverse events in both treatment groups, but these were transitory and no severe adverse event was recorded during the study period. Safety parameters were maintained throughout the study in both treatment groups. The combination of uridine, cytidine, and vitamin B~12~ was safe and effective in the treatment of neuralgias arising from neural compression associated with degenerative orthopedic alterations and trauma. Considering these results, a prospective, multi-center randomized controlled clinical trial, comparing the activity of vitamin B~12~ alone to the activity of vitamin B~12~ in combination with nucleotides in pain reduction, is warranted.
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![Flowchart of subjects through the study](jpr-10-397Fig1){#f1-jpr-10-397}

![Patient overall assessment: graded on a 10 point scale from 1 (worst assessment of overall condition) to 10 (best assessment of overall condition) for treatment groups A and B at each study visit.\
**Note:** Group A: subjects treated with uridine, cytidine, and vitamin B12. Group B: subjects treated with vitamin B12 alone.](jpr-10-397Fig2){#f2-jpr-10-397}

![Physician overall assessment: graded on a 10 point scale from 1 (worst assessment of overall condition) to 10 (best assessment of overall condition) for treatment groups A and B at each study visit.\
**Note:** Group A: subjects treated with uridine, cytidine, and vitamin B12. Group B: subjects treated with vitamin B12 alone.](jpr-10-397Fig3){#f3-jpr-10-397}

![Visual analog scale scores for pain, for treatment groups A and B. **Note:** Group A: subjects treated with uridine, cytidine, and vitamin B12. Group B: subjects treated with vitamin B12 alone.\
**Abbreviations:** PT, pretreatment; VAS, visual analog scale; V2, visit two (after 15 days of treatment); V3, visit three (after 30 days of treatment).](jpr-10-397Fig4){#f4-jpr-10-397}

###### 

Pretreatment and demographic data

  Variable                      Results                           
  ----------------------------- ---------------- ---------------- ------------
  Gender                                                          *p*=0.6998
   Male                         98               114              
   Female                       102              86               
  Age (years)                   43.74 (±9.73)    44.12 (±10.22)   *p*=0.133
  Height (cm)                   166.91 (±9.23)   168.49 (±8.86)   *p*=0.0824
  Ethnicity                                                       *p*=0.314
   Asian                        2                0                
   Black                        71               83               
   Caucasian                    90               86               
   Mulatto                      37               31               
  Pain location                                                   *p*=0.5112
   Back pain                    125              127              
   Hip pain                     45               37               
   Carpal tunnel syndrome       30               36               
  Overall diet                                                    *p*=0.415
   Good                         72               61               
   Moderate                     87               99               
   Poor                         41               40               
  Alcohol consumption                                             *p*=0.57
   None                         63               72               
   ≤2 drinks/day                82               73               
   \>2 drinks/day               55               55               
  Cigarette smoking                                               *p*=0.102
   Non-smoker                   91               78               
   \<10 cigarettes/day          54               47               
   ≥10 cigarettes/day           55               75               
  Manual labor                                                    *p*=0.309
   Light                        57               68               
   Moderate                     69               56               
   Heavy                        74               76               
  Physical exercise                                               *p*=0.415
   Regular (at least 1×/week)   49               41               
   Irregular                    81               77               
   None                         70               82               

**Notes:** Data are n, or mean (±standard deviation). Group A: subjects treated with uridine, cytidine, and vitamin B12. Group B: subjects treated with vitamin B12 alone.

###### 

Safety assessments

  Parameters                         Results          
  ---------------------------------- ---------------- ----------------
  Weight (kg)                                         
   Pretreatment                      72.27 (±12.29)   74.05 (±12.27)
   Visit two                         72.35 (±12.28    73.87 (±12.29)
   Visit three                       72.42 (±12.31)   74.04 (±12.39)
  BMI                                                 
   Pretreatment                      25.80 (±3.03)    25.99 (±3.05)
   Visit two                         25.80 (±3.013)   25.96 (±3.099)
   Visit three                       25.82 (±3.009)   26.02 (±3.121)
  Systolic blood pressure (mmHg)                      
   Pretreatment                      123.7 (±8.541)   123.7 (±7.285)
   Visit two                         122.4 (±7.376)   122.7 (±8.124)
   Visit three                       122.4 (±7.813)   123.0 (±7.644)
  Diastolic blood presssure (mmHg)                    
   Pretreatment                      80.29 (±7.42)    80.14 (±8.269)
   Visit two                         79.67 (±7.755)   79.43 (±8.655)
   Visit three                       80.04 (±7.576)   79.38 (±8.672)
  Pulse (bpm)                                         
   Pretreatment                      68.54 (±4.644)   68.92 (±4.503)
   Visit two                         68.17 (±5.165)   68.47 (±5.647)
   Visit three                       68.30 (±4.789)   68.57 (±4.648)

**Notes:** Data are n, or mean (±standard deviation). Group A: subjects treated with uridine, cytidine, and vitamin B12. Group B: subjects treated with vitamin B12 alone.

**Abbreviations:** BMI, body mass index; bpm, beats per minute.

###### 

Adverse events considered to be associated with study drug administration

  Adverse event           Severity   Number of affected subjects
  ----------------------- ---------- -----------------------------
  **Group A**                        
  Abdominal colic         Mild       1
  Abdominal discomfort    Moderate   1
  Abdominal distension    Moderate   2
  Abdominal distension    Mild       1
  Abdominal disturbance   Moderate   1
  Feeling of bloating     Moderate   1
  Flatulence              Moderate   1
  Increased appetite      Mild       1
  Nausea                  Moderate   1
  Nausea                  Mild       3
  **Group B**                        
  Abdominal discomfort    Mild       1
  Abdominal distension    Moderate   1
  Abdominal distension    Mild       1
  Constipation            Moderate   1
  Constipation            Mild       1
  Elevated uric acid      Mild       2
  Epigastralgia           Mild       2
  Epigastralgia           Moderate   1
  Flatulence              Mild       1
  Nausea                  Moderate   1
  Nausea                  Mild       1

**Note:** Group A: subjects treated with uridine, cytidine, and vitamin B12. Group B: subjects treated with vitamin B12 alone.
